We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




DNA-Constructed Nanoparticles Safely Target Tumors

By LabMedica International staff writers
Posted on 17 Feb 2014
Print article
A team of Canadian researchers has discovered a way to assemble “building blocks” of gold nanoparticles as the vehicle to deliver cancer medications or cancer-identifying markers directly into cancerous tumors.

The study, led by Prof. Warren Chan, of University of Institute of Biomaterials & Biomedical Engineering (IBBME; ON, Canada) and the Donnelly Center for Cellular & Biomolecular Research, was published February 2014 in the journal Nature Nanotechnology.

“To get materials into a tumor they need to be a certain size,” explained Prof. Chan. “Tumors are characterized by leaky vessels with holes roughly 50–500 nm in size, depending on the tumor type and stage. The goal is to deliver particles small enough to get through the holes and ‘hang out’ in the tumor’s space for the particles to treat or image the cancer. If particle is too large, it can’t get in, but if the particle is too small, it leaves the tumor very quickly.”

Prof. Chan and his researchers solved this problem by creating modular structures “glued” together with DNA. “We’re using a ‘molecular assembly’ model—taking pieces of materials that we can now fabricate accurately and organizing them into precise architectures, like putting LEGO blocks together,” said Leo Chou, a fifth-year PhD, student at IBBME and first author of the paper. “The major advantage of this design strategy is that it is highly modular, which allows you to ‘swap’ components in and out,” he said. “This makes it very easy to create systems with multiple functions, or screen a large library of nanostructures for desirable biological behaviors."

The long-term risk of toxicity from particles that linger in the body, however, has been a serious hurdle to nanomedical research. “Imagine you’re a cancer patient in your 30s,” said Prof. Chan. “And you’ve had multiple injections of these metal particles. By the time you’re in your mid-40s these are likely to be retained in your system and could potentially cause other problems.”

Although DNA is flexible, and over time, the body’s natural enzymes cause the DNA to degrade, and the grouping breaks apart. The body then eliminates the smaller particles safely and easily. But while the researchers are excited about this breakthrough, Prof. Chan stressed that a lot more details need to be determined. “We need to understand how DNA design influences the stability of things, and how a lack of stability might be helpful or not,” he said. “The use of assembly to build complex and smart nanotechnology for cancer applications is still in the very primitive stage of development. Still, it is very exciting to be able to see and test the different nanoconfigurations for cancer applications.”

Related Links:
University of Toronto’s Institute of Biomaterials & Biomedical Engineering


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.